Physician profile

Curtiss Johnson

Optometrist · Fernley, NV

NPI 1245234921

$1,450.30

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$788.95

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Johnson & Johnson Vision Care, INC. $423.60 2021-2024 Acuvue
Biotissue Holdings INC. $384.04 2024
Dompe US, INC. $123.45 2021
Coopervision INC. $119.85 2019-2023 Myday Contact Lens
Sight Sciences, INC. $113.85 2020
Bausch & Lomb Americas INC. $106.82 2023 Revive
Tarsus Pharmaceuticals, INC. $105.51 2024 Xdemvy
Alcon Vision LLC $48.73 2019-2023 Total30
Bausch & Lomb, A Division of Bausch Health US, LLC $24.45 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Curtiss Johnson

$1,450.30

in general payments reported 2019-2025

Years
2019-2024
Top company
Johnson & Johnson Vision Care, INC.

https://glasscript.com/doctor/654939/curtiss-johnson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.